Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Fong · SciRah

Researcher profile · Semantic Scholar

P. Fong

Share profile

P. Fong — researcher profile on SciRah

h-index: 31
Works: 116
Citations: 8,031

Most-cited papers

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong, D. Boss, T. Yap, A. Tutt +11 more
2009New England Journal of Medicine3,602 citations Open access
Semantic Scholar
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
P. Fong, T. Yap, D. Boss, C. Carden +14 more
2010Journal of Clinical Oncology1,004 citations Open access
Semantic Scholar
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
N. Agarwal, A. Azad, J. Carles, A. Fay +17 more
2023The Lancet388 citations Open access
Semantic Scholar
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
D. Olmos, H. Arkenau, J. Ang, I. Ledaki +11 more
2009Annals of Oncology265 citations Open access
Semantic Scholar
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
S. Sandhu, K. Papadopoulos, P. Fong, A. Patnaik +10 more
2013Cancer Chemotherapy and Pharmacology264 citations
Semantic Scholar
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
L. Molife, G. Attard, P. Fong, V. Karavasilis +9 more
2010Annals of Oncology185 citations Open access
Semantic Scholar
Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
J. de Bono, R. Kristeleit, A. Tolcher, P. Fong +11 more
2008Clinical Cancer Research119 citations Open access
Semantic Scholar
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
E. Antonarakis, S. Park, Jeffrey C. Goh, S. Shin +27 more
2023Journal of Clinical Oncology115 citations Open access
Semantic Scholar
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
F. Saad, K. Fizazi, V. Jinga, E. Efstathiou +14 more
2015The Lancet Oncology114 citations Open access
Semantic Scholar
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
J. Ledermann, A. Oza, D. Lorusso, C. Aghajanian +20 more
2020The Lancet Oncology110 citations Open access
Semantic Scholar
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors
I. Ray-Coquard, Jubilee Brown, P. Harter, D. Provencher +8 more
2014International Journal of Gynecologic Cancer102 citations Open access
Semantic Scholar
AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study
P. Fong, D. Boss, C. Carden, M. Roelvink +6 more
200885 citations
Semantic Scholar
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L. Molife, P. Fong, L. Paccagnella, A. Reid +14 more
2010British Journal of Cancer84 citations Open access
Semantic Scholar
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
G. Konecny, N. Finkler, Agustin Garcia, D. Lorusso +8 more
2015The Lancet Oncology83 citations
Semantic Scholar
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
C. Marth, I. Vergote, G. Scambia, W. Oberaigner +20 more
2017European Journal of Cancer72 citations Open access
Semantic Scholar
Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up.
M. Wilson, P. Fong, S. Mesnage, K. Chrystal +8 more
2015Gynecologic Oncology67 citations
Semantic Scholar
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Evan Y. Yu, J. Piulats, G. Gravis, P. Fong +17 more
2022European Urology66 citations Open access
Semantic Scholar
Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
Evan Y. Yu, C. Massard, M. Retz, A. Tafreshi +14 more
2019Journal of Clinical Oncology55 citations
Semantic Scholar
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
P. Grivas, E. Kopyltsov, Po-Jung Su, F. Parnis +12 more
2022European Urology47 citations Open access
Semantic Scholar
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
N. Agarwal, A. Azad, J. Carles, A. Fay +16 more
2023Journal of Clinical Oncology46 citations
Semantic Scholar
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
D. O'Malley, A. Oza, D. Lorusso, C. Aghajanian +18 more
2022Gynecologic Oncology45 citations Open access
Semantic Scholar
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
J. de Bono, J. Piulats, H. Pandha, D. Petrylak +9 more
2014Clinical Cancer Research44 citations Open access
Semantic Scholar
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
R. Broom, V. Hinder, K. Sharples, J. Proctor +12 more
2015Clinical Genitourinary Cancer42 citations
Semantic Scholar
KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Evan Y. Yu, J. Piulats, G. Gravis, B. Laguerre +16 more
202040 citations
Semantic Scholar
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
A. Oza, D. Lorusso, C. Aghajanian, A. Oaknin +24 more
2019Journal of Clinical Oncology34 citations Open access
Semantic Scholar
Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression.
R. Rosario, M. Wilson, Wei-Tzu Cheng, K. Payne +3 more
2013Gynecologic Oncology33 citations
Semantic Scholar
Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)
R. de Wit, K. Fizazi, V. Jinga, E. Efstathiou +11 more
201430 citations
Semantic Scholar
O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
R. Coleman, A. Oza, D. Lorusso, C. Aghajanian +15 more
2022Oral Abstracts (Regular and Late-Breaking Submission)24 citations Open access
Semantic Scholar
MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markers
Wei-Tzu Cheng, R. Rosario, A. Muthukaruppan, M. Wilson +4 more
2017Clinical Epigenetics23 citations Open access
Semantic Scholar
Development and validation of a targeted gene sequencing panel for application to disparate cancers
M. McCabe, Marie-Emilie A. Gauthier, Chia-Ling Chan, T. Thompson +135 more
2019Scientific Reports22 citations Open access
Semantic Scholar
2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
R. Coleman, A. Oza, D. Lorusso, C. Aghajanian +15 more
2022Ovarian cancer21 citations Open access
Semantic Scholar
KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
W. Berry, P. Fong, J. Piulats, L. Appleman +16 more
201916 citations
Semantic Scholar
Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
P. Fong, M. Retz, A. Drakaki, C. Massard +15 more
2019Journal of Clinical Oncology16 citations
Semantic Scholar
Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).
J. Ang, T. Yap, P. Fong, C. Carden +6 more
201016 citations
Semantic Scholar
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
N. Colombo, A. Oza, D. Lorusso, C. Aghajanian +22 more
2020Gynecologic Oncology15 citations Open access
Semantic Scholar
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
J. Desai, P. Fong, V. Moreno, S. Frentzas +10 more
2023British Journal of Cancer14 citations Open access
Semantic Scholar
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
K. Fizazi, A. Azad, N. Matsubara, J. Carles +15 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase 3 trial ARIEL3
A. Clamp, D. Lorusso, A. Oza, C. Aghajanian +19 more
2021International Journal of Gynecological Cancer13 citations Open access
Semantic Scholar
Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
Evan Y. Yu, Jose Maria M. Piulats Rodriguez, G. Gravis, B. Laguerre +16 more
2020Journal of Clinical Oncology12 citations
Semantic Scholar
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.
L. Albiges, K. Beckermann, Wilson H. Miller, Jeffrey C. Goh +15 more
2023Journal of Clinical Oncology11 citations Open access
Semantic Scholar
73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
Evan Y. Yu, J. Piulats, G. Gravis, P. Fong +14 more
2021Annals of Oncology10 citations Open access
Semantic Scholar
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.
A. Azad, K. Fizazi, N. Matsubara, F. Saad +15 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
E. Yu, J. M. Piulats, G. Gravis, P. Fong +16 more
2021Annals of Oncology7 citations Open access
Semantic Scholar
The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
R. Lawrenson, Z. Obertova, Charis Brown, P. Fong +3 more
2014Journal of Cancer7 citations Open access
Semantic Scholar
LBA27PHASE 2 STUDY OF SECOND-LINE DOVITINIB (TKI258) IN PATIENTS WITH FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2)-MUTATED OR -NONMUTATED ADVANCED AND/OR METASTATIC ENDOMETRIAL CANCER
G. Konecny, N. Finkler, A. Garcia, D. Lorusso +8 more
20147 citations Open access
Semantic Scholar
PD16-12 PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C
Evan Y. Yu, P. Fong, J. Piulats, L. Appleman +15 more
20206 citations Open access
Semantic Scholar
Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.
Evan Y. Yu, C. Massard, M. Retz, A. Tafreshi +14 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
C. Massard, M. Retz, P. Hammerer, F. Quevedo +15 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].
Evan Y. Yu, J. Piulats, G. Gravis, P. Fong +17 more
2022European Urology5 citations Open access
Semantic Scholar
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
H. Conter, N. Shore, W. Berry, P. Fong +16 more
20205 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. de Bono×22
Invite
J. de Bono — researcher profile on SciRah
Evan Y. Yu×13
Invite
Evan Y. Yu — researcher profile on SciRah
C. Poehlein×12
Invite
C. Poehlein — researcher profile on SciRah
H. Gurney×12
Invite
H. Gurney — researcher profile on SciRah

×12

Invite

C. Schloss — researcher profile on SciRah

Invite

N. Shore — researcher profile on SciRah

Invite

M. Retz — researcher profile on SciRah

Invite

D. Lorusso — researcher profile on SciRah

Invite

J. Piulats — researcher profile on SciRah

Jeffrey C. Goh×9

Invite

Jeffrey C. Goh — researcher profile on SciRah

Invite

A. Oza — researcher profile on SciRah

Invite

N. Colombo — researcher profile on SciRah